OpenURL Connection Search

Select item for more details and to access through your institution.

Prediction of prostate cancer aggressiveness using 18F-Fluciclovine (FACBC) PET and multisequence multiparametric MRI.
Published in:
Scientific Reports, 2020, v. 10, n. 1, p. 1, doi. 10.1038/s41598-020-66255-8
By:
- Movahedi, Parisa;
- Merisaari, Harri;
- Perez, Ileana Montoya;
- Taimen, Pekka;
- Kemppainen, Jukka;
- Kuisma, Anna;
- Eskola, Olli;
- Teuho, Jarmo;
- Saunavaara, Jani;
- Pesola, Marko;
- Kähkönen, Esa;
- Ettala, Otto;
- Liimatainen, Timo;
- Pahikkala, Tapio;
- Boström, Peter;
- Aronen, Hannu;
- Minn, Heikki;
- Jambor, Ivan
Publication type:
Article
Correlation between 18F-1-amino-3-fluorocyclobutane-1-carboxylic acid (18F-fluciclovine) uptake and expression of alanine-serine-cysteine-transporter 2 (ASCT2) and L-type amino acid transporter 1 (LAT1) in primary prostate cancer.
Published in:
EJNMMI Research, 2019, v. 9, n. 1, p. N.PAG, doi. 10.1186/s13550-019-0518-5
By:
- Saarinen, Irena;
- Jambor, Ivan;
- Kim, Mai;
- Kuisma, Anna;
- Kemppainen, Jukka;
- Merisaari, Harri;
- Eskola, Olli;
- Koskenniemi, Anna-Riina;
- Perez, Ileana Montoya;
- Boström, Peter;
- Taimen, Pekka;
- Minn, Heikki
Publication type:
Article
Comparison of standardized uptake values between 99mTc-HDP SPECT/CT and 18F-NaF PET/CT in bone metastases of breast and prostate cancer.
Published in:
EJNMMI Research, 2019, v. 9, n. 1, p. 1, doi. 10.1186/s13550-019-0475-z
By:
- Arvola, Samuli;
- Jambor, Ivan;
- Kuisma, Anna;
- Kemppainen, Jukka;
- Kajander, Sami;
- Seppänen, Marko;
- Noponen, Tommi
Publication type:
Article
Safety, biodistribution and radiation dosimetry of 18F-rhPSMA-7.3 in healthy adult volunteers.
Published in:
Journal of Nuclear Medicine, 2020, v. 61, n. 12, p. 1, doi. 10.2967/jnumed.120.252114
By:
- Tolvanen, Tuula;
- Kalliokoski, Kari;
- Malaspina, Simona;
- Kuisma, Anna;
- Lahdenpohja, Salla;
- Postema, Ernst J.;
- Miller, Matthew P.;
- Scheinin, Mika
Publication type:
Article
Safety, biodistribution and radiation dosimetry of 18F-rhPSMA-7.3 in healthy adult volunteers.
Published in:
Journal of Nuclear Medicine, 2020, v. 61, n. 11, p. 1, doi. 10.2967/jnumed.120.252114
By:
- Tolvanen, Tuula;
- Kalliokoski, Kari;
- Malaspina, Simona;
- Kuisma, Anna;
- Lahdenpohja, Salla;
- Postema, Ernst J.;
- Miller, Matthew P.;
- Scheinin, Mika
Publication type:
Article
Safety, biodistribution and radiation dosimetry of 18F-rhPSMA-7.3 in healthy adult volunteers.
Published in:
Journal of Nuclear Medicine, 2020, v. 61, n. 10, p. 1, doi. 10.2967/jnumed.120.252114
By:
- Tolvanen, Tuula;
- Kalliokoski, Kari;
- Malaspina, Simona;
- Kuisma, Anna;
- Lahdenpohja, Salla;
- Postema, Ernst J.;
- Miller, Matthew P.;
- Scheinin, Mika
Publication type:
Article
Long-term outcome of biologically guided dose-escalated radiotherapy of localized prostate cancer.
Published in:
Acta Oncologica, 2022, v. 61, n. 1, p. 97, doi. 10.1080/0284186X.2021.1998613
By:
- Kuisma, Anna;
- Wright, Pauliina;
- Suilamo, Sami;
- Seppälä, Jan;
- Koivisto, Mari;
- Lindholm, Paula;
- Minn, Heikki
Publication type:
Article
Prospective evaluation of planar bone scintigraphy, SPECT, SPECT/CT, F-NaF PET/CT and whole body 1.5T MRI, including DWI, for the detection of bone metastases in high risk breast and prostate cancer patients: SKELETA clinical trial.
Published in:
Acta Oncologica, 2016, v. 55, n. 1, p. 59, doi. 10.3109/0284186X.2015.1027411
By:
- Jambor, Ivan;
- Aronen, Hannu J.;
- Kuisma, Anna;
- Ramadan, Susan;
- Huovinen, Riikka;
- Minn, Heikki;
- Sandell, Minna;
- Auren, Joakim;
- Saunavaara, Jani;
- Kajander, Sami;
- Kemppainen, Jukka;
- Merisaari, Harri;
- Seppänen, Marko;
- Kauppila, Esa;
- Noponen, Tommi
Publication type:
Article
Kinetic analysis and optimisation of 18F-rhPSMA-7.3 PET imaging of prostate cancer.
Published in:
European Journal of Nuclear Medicine & Molecular Imaging, 2021, v. 48, n. 11, p. 3723, doi. 10.1007/s00259-021-05346-8
By:
- Malaspina, Simona;
- Oikonen, Vesa;
- Kuisma, Anna;
- Ettala, Otto;
- Mattila, Kalle;
- Boström, Peter J.;
- Minn, Heikki;
- Kalliokoski, Kari;
- Postema, Ernst J.;
- Miller, Matthew P.;
- Scheinin, Mika
Publication type:
Article
Prospective evaluation of F-FACBC PET/CT and PET/MRI versus multiparametric MRI in intermediate- to high-risk prostate cancer patients (FLUCIPRO trial).
Published in:
European Journal of Nuclear Medicine & Molecular Imaging, 2018, v. 45, n. 3, p. 355, doi. 10.1007/s00259-017-3875-1
By:
- Jambor, Ivan;
- Kuisma, Anna;
- Kähkönen, Esa;
- Kemppainen, Jukka;
- Merisaari, Harri;
- Eskola, Olli;
- Teuho, Jarmo;
- Perez, Ileana Montoya;
- Pesola, Marko;
- Aronen, Hannu J.;
- Boström, Peter J.;
- Taimen, Pekka;
- Minn, Heikki
Publication type:
Article

Found: 10

Prediction of prostate cancer aggressiveness using 18F-Fluciclovine (FACBC) PET and multisequence multiparametric MRI.

Correlation between <sup>18</sup>F-1-amino-3-fluorocyclobutane-1-carboxylic acid (<sup>18</sup>F-fluciclovine) uptake and expression of alanine-serine-cysteine-transporter 2 (ASCT2) and L-type amino acid transporter 1 (LAT1) in primary prostate cancer.

Comparison of standardized uptake values between <sup>99m</sup>Tc-HDP SPECT/CT and <sup>18</sup>F-NaF PET/CT in bone metastases of breast and prostate cancer.

Safety, biodistribution and radiation dosimetry of <sup>18</sup>F-rhPSMA-7.3 in healthy adult volunteers.

Safety, biodistribution and radiation dosimetry of <sup>18</sup>F-rhPSMA-7.3 in healthy adult volunteers.

Safety, biodistribution and radiation dosimetry of <sup>18</sup>F-rhPSMA-7.3 in healthy adult volunteers.

Long-term outcome of biologically guided dose-escalated radiotherapy of localized prostate cancer.

Prospective evaluation of planar bone scintigraphy, SPECT, SPECT/CT, F-NaF PET/CT and whole body 1.5T MRI, including DWI, for the detection of bone metastases in high risk breast and prostate cancer patients: SKELETA clinical trial.

Kinetic analysis and optimisation of <sup>18</sup>F-rhPSMA-7.3 PET imaging of prostate cancer.

Prospective evaluation of F-FACBC PET/CT and PET/MRI versus multiparametric MRI in intermediate- to high-risk prostate cancer patients (FLUCIPRO trial).